Every-other-month injectable cabotegravir and rilpivirine suppresses viral load for two years
Long-acting cabotegravir (Vocabria) and rilpivirine (Rekambys) injections maintain viral suppression for two years, according to follow-up study results presented this week at the Conference on Retroviruses and Opportunistic Infections (CROI). The European Medicines Agency (EMA) approved the injectable combination — the first complete HIV regimen that does not require daily pills — in December 2020.… Read More »